Banking

Brokerages Expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Will Announce Quarterly Sales of $3.21 Million

Wall Street brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to announce $3.21 million in sales for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $5.50 million and the lowest estimate coming in at $400,000.00. Syros Pharmaceuticals posted sales of $510,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 529.4%. The firm is scheduled to report its next earnings report on Thursday, March 4th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $12.60 million for the current fiscal year, with estimates ranging from $9.81 million to $14.90 million. For the next financial year, analysts forecast that the firm will report sales of $8.78 million, with estimates ranging from $1.60 million to $15.31 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, November 5th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.05). Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 94.59%. The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $2.83 million.

A number of equities analysts have commented on the company. Roth Capital boosted their price objective on Syros Pharmaceuticals from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. ValuEngine downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 23rd. HC Wainwright raised shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $15.00 in a report on Wednesday, November 4th. Brookline Capital Management began coverage on shares of Syros Pharmaceuticals in a research note on Tuesday, November 10th. They issued a “buy” rating and a $19.00 target price for the company. Finally, Oppenheimer started coverage on shares of Syros Pharmaceuticals in a research note on Friday, November 6th. They set a “buy” rating and a $13.00 price target on the stock. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $15.78.

In other news, Director Richard A. Young sold 5,673 shares of the stock in a transaction on Monday, October 19th. The stock was sold at an average price of $8.75, for a total value of $49,638.75. Following the transaction, the director now owns 335,201 shares of the company’s stock, valued at approximately $2,933,008.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 14.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System bought a new position in Syros Pharmaceuticals during the second quarter worth about $228,000. FMR LLC grew its holdings in Syros Pharmaceuticals by 5.5% during the second quarter. FMR LLC now owns 6,623,200 shares of the company’s stock valued at $70,603,000 after purchasing an additional 344,216 shares during the period. California Public Employees Retirement System increased its stake in Syros Pharmaceuticals by 170.6% in the second quarter. California Public Employees Retirement System now owns 94,694 shares of the company’s stock valued at $1,009,000 after purchasing an additional 59,697 shares in the last quarter. Vanguard Group Inc. raised its holdings in Syros Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 1,901,373 shares of the company’s stock worth $20,269,000 after purchasing an additional 103,005 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Syros Pharmaceuticals by 29.1% during the second quarter. New York State Common Retirement Fund now owns 40,400 shares of the company’s stock worth $431,000 after purchasing an additional 9,100 shares in the last quarter. Institutional investors and hedge funds own 97.66% of the company’s stock.

NASDAQ SYRS opened at $13.08 on Friday. The stock’s 50 day simple moving average is $9.31 and its 200 day simple moving average is $10.08. Syros Pharmaceuticals has a one year low of $4.26 and a one year high of $15.65. The firm has a market cap of $599.21 million, a PE ratio of -7.69 and a beta of 1.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.85 and a quick ratio of 4.85.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Article: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syros Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Related Articles

Back to top button